Literature DB >> 3471902

Essential hereditary hypertension in dogs: a new animal model.

K C Bovée, M P Littman, F Saleh, R Beeuwkes, W r Pn, L B Kinter.   

Abstract

The objective of this project is to characterize a genetically determined model of essential hypertension in dogs. A pair of unrelated dogs with essential hypertension were identified. Breeding of these dogs and back-cross matings have resulted in 24 offspring, approximately half of which have essential hypertension (systolic blood pressure 170 mmHg, diastolic 105 mmHg). Other offspring are either borderline hypertensive or normal. Blood pressure is measured in the trained, unanaesthetized state by direct arterial puncture. Offspring have normal plasma chemistries, electrolytes, glomerular filtration rate, plasma renin activity, aldosterone and catecholamines. These dogs appear to salt-sensitive compared with normal dogs. Further breeding studies will characterize this new model of hereditary essential hypertension.

Entities:  

Mesh:

Year:  1986        PMID: 3471902

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

1.  Relationships between degree of azotaemia and blood pressure, urinary protein:creatinine ratio and fractional excretion of electrolytes in dogs with renal azotaemia.

Authors:  C Buranakarl; K Ankanaporn; S Thammacharoen; M Trisiriroj; T Maleeratmongkol; P Thongchai; S Panasjaroen
Journal:  Vet Res Commun       Date:  2006-12-20       Impact factor: 2.459

2.  Ocular lesions associated with systemic hypertension in dogs: 65 cases (2005-2007).

Authors:  Nicole L Leblanc; Rebecca L Stepien; Ellison Bentley
Journal:  J Am Vet Med Assoc       Date:  2011-04-01       Impact factor: 1.936

3.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.